Description
Foreword – RNA technology overview Dong Yu (dong.x.yu@gsk.com) (GSK) & Frank Bahner (Frank.Baehner@curevac.com) (CureVac) – confirmed Conventional mRNA-based technology & mode of action Benjamin Petsch (benjamin.petsch@curevac.com) (CureVac) – confirmed Self-amplifying RNA-based technology & mode of action Jeffrey Ulmer (jeffrey.b.ulmer@gsk.com)/Dong Yu (dong.x.yu@gsk.com) (GSK) – confirmed Delivery and formulation technologies Yizhou Dong (dong.525@osu.edu) (Ohio State) – confirmed RNA for infectious disease applications Drew Weissman (dreww@pennmedicine.upenn.edu) (U Penn) – confirmed RNA for other indications (immunotherapies/oncology, molecular therapies – a potential topic) Tim Wagenaar (Timothy.Wagenaar@sanofi.com) (Sanofi) – tentatively confirmed, likely working with Biotech; Backup – Katalin Kariko (BioNTech) Production and capabilities Heinrich Haas (Heinrich.Haas@biontech.de) (Biontech) – waiting for response; Backup – Juan Andres (Moderna) Clinical development Tal Zaks (Tal.Zaks@modernatx.com) (Moderna) – tentatively confirmed; Backup – Anna Collen (AstraZeneca) Other considerations (e.g., safety, regulatory issues, challenges) Mark Tracy (mark@tracybioconsulting.com) (Tracy Bioconsulting) – waiting for response
